RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
Regulatory Agency Hub

FDA CDER Updates

The latest guidances, approvals, and safety alerts from FDA CDER, curated by automated regulatory intelligence.

GUIDANCE FINAL
E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry
FDA (CDER) • Published: Oct 30, 2026

Clarifies how sponsors should evaluate and document QT/QTc interval prolongation and proarrhythmic risk during both clinical studies and nonclinical…

cardiology
clinical
+4
View update →
GUIDANCE FINAL
Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle
FDA (CDER) • Published: Oct 20, 2026

Clarifies how to submit clinical trial data intended to support the ability to operate a motor vehicle, including expectations for generating and presenting…

clinical
safety
+2
View update →
GUIDANCE FINAL
Regulatory Considerations for Prescription Drug Use-Related Software
FDA (CDER) • Published: Oct 20, 2026

Clarifies how FDA expects firms to assess and manage risks when prescription drug use-related software is introduced into clinical care workflows, with an…

manufacturing
quality
+3
View update →
GUIDANCE FINAL
Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators
FDA (CDER) • Published: Oct 19, 2026

Clarifies and standardizes safety reporting obligations for IND sponsors and for sponsors conducting BA/BE studies, aiming to ensure timely submission of…

clinical
safety
View update →
GUIDANCE FINAL
Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers
FDA (CDER) • Published: Oct 9, 2026

Clarifies how FDA expects sponsors of biosimilar and interchangeable biosimilar products to manage and document postapproval manufacturing changes, including…

manufacturing
quality
+3
View update →
GUIDANCE FINAL
Questions and Answers on Biosimilar Development and the BPCI Act: Guidance for Industry
FDA (CDER) • Published: Oct 9, 2026

Clarifies how FDA expects sponsors to develop, evaluate, and submit biosimilar applications under the BPCI Act, with emphasis on demonstrating…

immunology
infectious_disease
+16
View update →
GUIDANCE FINAL
Study Data Technical Conformance Guide - Technical Specifications Document
FDA (CDER) • Published: Oct 8, 2026

Provides FDA/CDER technical conformance expectations for study data submissions, guiding sponsors on how to structure and format data to support regulatory…

clinical
safety
+1
View update →
GUIDANCE FINAL
E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility
FDA (CDER) • Published: Oct 1, 2026

Establishes standardized E2B(R3) electronic transmission requirements for individual case safety reports (ICSRs), including detailed data elements and message…

safety
clinical
View update →
GUIDANCE FINAL
Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates: Guidance for Industry
FDA (CDER) • Published: Sep 8, 2026

Establishes temporary FDA policy for compounding certain starter parenteral nutrition products intended for neonates, aiming to maintain supply while…

pediatrics
gastroenterology
View update →
GUIDANCE DRAFT
Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing
FDA (CDER) • Published: Sep 2, 2026

Clarifies how pharmacokinetic (PK) studies should be designed and analyzed to evaluate drug exposure in patients with impaired hepatic function, with the goal…

clinical
safety
+6
View update →
GUIDANCE DRAFT
Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling
FDA (CDER) • Published: Sep 2, 2026

Clarifies how pharmacokinetic studies in patients with impaired hepatic function should be designed and analyzed to support labeling recommendations, with an…

clinical
safety
+2
View update →
GUIDANCE FINAL
Evaluation of Therapeutic Equivalence
FDA (CDER) • Published: Aug 21, 2026

Clarifies FDA expectations for demonstrating therapeutic equivalence for approved drug products, with emphasis on the evidentiary basis used to support…

clinical
manufacturing
+16
View update →
GUIDANCE DRAFT
Determining Whether to Submit an ANDA or a 505(b)(2) Application
FDA (CDER) • Published: Aug 17, 2026

Clarifies the decision logic and evidentiary expectations for applicants determining whether a generic drug should be filed as an ANDA or supported via a…

manufacturing
quality
+3
View update →
GUIDANCE DRAFT
Container Closure Systems for Human Drugs and Biological Products
FDA (CDER) • Published: Aug 13, 2026

Provides draft FDA recommendations on the design, qualification, and control of container closure systems (CCS) for human drugs and biological products…

manufacturing
quality
+3
View update →
GUIDANCE FINAL
Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products
FDA (CDER) • Published: Aug 12, 2026

Clarifies how FDA will conduct and manage formal meetings with sponsors/applicants for PDUFA-related products, including expectations for requests, agenda, and…

clinical
safety
+3
View update →
GUIDANCE DRAFT
Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts
FDA (CDER) • Published: Jul 31, 2026

Topic: Status: Draft.

View update →
GUIDANCE FINAL
Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs: Guidance for Industry
FDA (CDER) • Published: Jul 31, 2026

Topic: Status: Final.

View update →
GUIDANCE DRAFT
Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs: Draft Guidance for Industry
FDA (CDER) • Published: Jul 31, 2026

Topic: Status: Draft.

View update →
GUIDANCE FINAL
Psychedelic Drugs: Considerations for Clinical Investigations
FDA (CDER) • Published: Jul 14, 2026

Outlines FDA’s key considerations for designing, conducting, and monitoring clinical investigations involving psychedelic drugs, with an emphasis on patient…

psychiatry
neurology
+3
View update →
GUIDANCE FINAL
Topical Dermatologic Corticosteroids: In Vivo Bioequivalence
FDA (CDER) • Published: Jul 14, 2026

Clarifies FDA expectations for demonstrating in vivo bioequivalence for topical dermatologic corticosteroid products, which may affect study design, bridging…

dermatology
clinical
View update →

Get FDA CDER alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service
  • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.